Boulevard Bio is a precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted, multi-specific medicines designed to set new therapeutic standards. Boulevard is advancing a pipeline of multi-specific antibodies grounded in a deep understanding of B cell disease biology to pair the right targets and modalities to the right disease across the spectrum of B cell-driven autoimmune conditions. The company was founded by pioneers in B cell biology and was incubated by Deerfield Management with molecules developed inside Deerfield Discovery and Development (3DC), the firm's internal therapeutics research and development engine.

Key Contact